Icodec is a novel recombinant insulin that has been developed to have an analogue of human insulin with distinct pharmacokinetic (PK) and pharmacodynamic (PD) properties, enabling its use for weekly (instead of daily) administrations in patients affected by diabetes mellitus. Here, INS is linked to diabetes mellitus.